U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H27NO5
Molecular Weight 361.4321
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHROMONAR

SMILES

CCOC(=O)COC1=CC2=C(C=C1)C(C)=C(CCN(CC)CC)C(=O)O2

InChI

InChIKey=KLOIYEQEVSIOOO-UHFFFAOYSA-N
InChI=1S/C20H27NO5/c1-5-21(6-2)11-10-17-14(4)16-9-8-15(12-18(16)26-20(17)23)25-13-19(22)24-7-3/h8-9,12H,5-7,10-11,13H2,1-4H3

HIDE SMILES / InChI

Molecular Formula C20H27NO5
Molecular Weight 361.4321
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://adisinsight.springer.com/drugs/800000219

Chromonar is a coronary vasodilator agent, it dilates coronary vessels and increases coronary blood flow volume rate, contributes to the development of collateral circulation (with prolonged use), improves metabolic processes in myocardium. The mechanism of action of a role played by its inhibitory effect on phosphodiesterase, accompanied by accumulation in the cells of cyclic 3 ', 5'-adenosine monophosphate. Due to the relatively low therapeutic efficacy Chromonar use is limited, mainly in the early stages of coronary heart disease with angina pectoris in the absence of long-standing and long strokes, when there is no expressed stenotic process.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Intensain

Approved Use

Indications for use: Angina without expressed stenotic process protracted and prolonged attacks, postinfarction period.
PubMed

PubMed

TitleDatePubMed
Cardioprotective effects of carbocromen in awake and anesthetized dogs with amitriptyline poisoning.
1985 Jul-Aug
Protective actions of carbocromene against amitriptyline-induced cardiotoxicity in anesthetized rats.
1986 Jan
Intradermal injection vs. oral treatment of tinnitus.
2001 Jul-Aug
Effect of estrogen replacement therapy on distribution of myocardial blood flow in female anesthetized rabbits.
2001 Sep
Preparation and characterization of solid lipid nanoparticles containing cloricromene.
2003 Oct-Dec
A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat.
2004 Apr 16
Cloricromene in endotoxemia: role of NF-kappaB.
2004 Aug
Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.
2004 Jul
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.
2006 Apr
Cloricromene effect on the enzyme activities of the tryptophan-nicotinic acid pathway in diabetic/hyperlipidemic rabbits.
2006 Jan 18
Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.
2006 Mar 24
Retinal and systemic pharmacokinetics of the anti-inflammatory drug cloricromene following oral administration in the rat and rabbit.
2007 Jun
Protective effects of a coumarin derivative in diabetic rats.
2009 Aug
Synthesis and vasorelaxant and platelet antiaggregatory activities of a new series of 6-halo-3-phenylcoumarins.
2010 Jan 12
Patents

Sample Use Guides

Inside after food: 0,075 - 0,15 g (1 - 2 tablets) 3 times a day. In more severe cases, to begin receiving 0.15 g 4 times a day, and after improving the dose is reduced to 0.075 g of 3 - 4 times daily. It is noted that the effect of the drug increases (to 10 - 30th day) and lasts a long time. Take in a few weeks or months (up to 6 months).
Route of Administration: Oral
In Vitro Use Guide
In bovine heart mitochondria ho/h-1 ratios in repeated scans increased in presence of carbocromen (20--40 umol/l)
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:12:30 UTC 2023
Edited
by admin
on Fri Dec 15 16:12:30 UTC 2023
Record UNII
R0C9NIE5JJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHROMONAR
MI  
Common Name English
ACETIC ACID, ((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)-, ETHYL ESTER
Common Name English
((3-(2-(DIETHYLAMINO)ETHYL)-4-METHYL-2-OXO-2H-1-BENZOPYRAN-7-YL)OXY)ACETIC ACID ETHYL ESTER
Systematic Name English
AG-3 FREE BASE
Code English
carbocromen [INN]
Common Name English
Carbocromen [WHO-DD]
Common Name English
A-27053 FREE BASE
Code English
CARBOCROMEN
INN   WHO-DD  
INN  
Official Name English
NSC-110430 FREE BASE
Code English
CHROMONAR [MI]
Common Name English
Classification Tree Code System Code
WHO-ATC C01DX05
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
NCI_THESAURUS C29707
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
WHO-VATC QC01DX05
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
Code System Code Type Description
WIKIPEDIA
CARBOCROMEN
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
CAS
804-10-4
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
DRUG CENTRAL
3098
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
FDA UNII
R0C9NIE5JJ
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
MERCK INDEX
m3513
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY Merck Index
SMS_ID
100000084566
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
EVMPD
SUB06612MIG
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
EPA CompTox
DTXSID60230301
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
NCI_THESAURUS
C79586
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
MESH
D002866
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
ECHA (EC/EINECS)
212-356-6
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
PUBCHEM
12604
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
INN
1677
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
RXCUI
2508
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY RxNorm
ChEMBL
CHEMBL163672
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
DRUG BANK
DB13279
Created by admin on Fri Dec 15 16:12:30 UTC 2023 , Edited by admin on Fri Dec 15 16:12:30 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY